Engineering protein thermostability using a generic activity-independent biophysical screen inside the cell

Nature Communications

Volumn 4, Issue , 2013, Pages

  Asial, Ignacio ^a   Cheng, Yue Xiang ^a   Engman, Henrik ^a   Dollhopf, Maria ^b   Wu, Binghuang ^a   Nordlund, Pär ^a,b   Cornvik, Tobias ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY; BIOENGINEERING; CELL ORGANELLE; DRUG; MUTATION; PROTEIN; STABILIZATION; TEMPERATURE EFFECT;

ARTICLE; CELL AGGREGATION; DRUG PROTEIN BINDING; HIGH THROUGHPUT SCREENING; HUMAN; IN VIVO STUDY; INTRACELLULAR SPACE; MEMBRANE FILTER; MOUSE; MUTAGENESIS; NONHUMAN; PROTEIN AGGREGATION; PROTEIN ENGINEERING; PROTEIN STABILITY; TEMPERATURE STRESS; THERMOSTABILITY;

BIOPHYSICS; CLONING, MOLECULAR; CRYSTALLOGRAPHY, X-RAY; DIRECTED MOLECULAR EVOLUTION; ENDOPEPTIDASES; GENE LIBRARY; HIGH-THROUGHPUT SCREENING ASSAYS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MODELS, MOLECULAR; PROTEIN ENGINEERING; PROTEIN STABILITY; SINGLE-CHAIN ANTIBODIES; SURFACE PLASMON RESONANCE;

EID: 84890936547     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3901     Document Type: Article

References (48)

1. Huus, K., Havelund, S., Olsen, H. B., van de Weert, M. & Frokjaer, S. Thermal dissociation and unfolding of insulin. Biochemistry 44, 11171-11177 (2005). (Pubitemid 41209053)
2. Mulinacci, F., Capelle, M. A., Gurny, R., Drake, A. F. & Arvinte, T. Stability of human growth hormone: influence of methionine oxidation on thermal folding. J. Pharm. Sci. 100, 451-463 (2011).
3. Radek, J. T. & Castellino, F. J. A differential scanning calorimetric investigation of the domains of recombinant tissue plasminogen activator. Arch. Biochem. Biophys. 267, 776-786 (1988). (Pubitemid 19020364)
4. Wakankar, A. A. et al. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. Bioconjug. Chem. 21, 1588-1595 (2010).
5. Willuda, J. et al. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res. 59, 5758-5767 (1999).
6. Arndt, M. A. et al. Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma. Int. J. Cancer 107, 822-829 (2003). (Pubitemid 37339738)
7. Schellekens, H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 1, 457-462 (2002). (Pubitemid 37361488)
8. Chirino, A. J. & Mire-Sluis, A. Characterizing biological products and assessing comparability following manufacturing changes. Nat. Biotechnol. 22, 1383-1391 (2004). (Pubitemid 39482857)
9. van den Burg, B. & Eijsink, V. G. Selection of mutations for increased protein stability. Curr. Opin. Biotechnol. 13, 333-337 (2002). (Pubitemid 35254091)
10. Eijsink, V. G., Gaseidnes, S., Borchert, T. V. & van den Burg, B. Directed evolution of enzyme stability. Biomol. Eng. 22, 21-30 (2005). (Pubitemid 40602590)
11. Ahmad, S., Kamal, M. Z., Sankaranarayanan, R. & Rao, N. M. Thermostable Bacillus subtilis lipases: in vitro evolution and structural insight. J. Mol. Biol. 381, 324-340 (2008).
12. Dumon, C. et al. Engineering hyperthermostability into a GH11 xylanase is mediated by subtle changes to protein structure. J. Biol. Chem. 283, 22557-22564 (2008).
13. Giver, L., Gershenson, A., Freskgard, P. O. & Arnold, F. H. Directed evolution of a thermostable esterase. Proc. Natl Acad. Sci. USA 95, 12809-12813 (1998). (Pubitemid 28509479)
14. Hao, J. & Berry, A. A thermostable variant of fructose bisphosphate aldolase constructed by directed evolution also shows increased stability in organic solvents. Prot. Eng. Des. Sel. 17, 689-697 (2004). (Pubitemid 40601889)
15. Warne, T. et al. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454, 486-491 (2008).
16. Warne, T., Serrano-Vega, M. J., Tate, C. G. & Schertler, G. F. Development and crystallization of a minimal thermostabilised G protein-coupled receptor. Prot. Expr. Purif. 65, 204-213 (2009).
17. Malawski, G. A. et al. Identifying protein construct variants with increased crystallization propensity-a case study. Prot. Sci. 15, 2718-2728 (2006). (Pubitemid 44833753)
18. Bloom, J. D., Labthavikul, S. T., Otey, C. R. & Arnold, F. H. Protein stability promotes evolvability. Proc. Natl Acad. Sci. USA 103, 5869-5874 (2006).
19. Lehmann, M. & Wyss, M. Engineering proteins for thermostability: the use of sequence alignments versus rational design and directed evolution. Curr. Opin. Biotechnol. 12, 371-375 (2001). (Pubitemid 32718790)
20. Dill, K. A. & MacCallum, J. L. The protein-folding problem, 50 years on. Science 338, 1042-1046 (2012).
21. Graslund, S. et al. Protein production and purification. Nat. Methods 5, 135-146 (2008).
22. Chayen, N. E. & Saridakis, E. Protein crystallization: from purified protein to diffraction-quality crystal. Nat. Methods 5, 147-153 (2008). (Pubitemid 351181740)
23. Sieber, V., Pluckthun, A. & Schmid, F. X. Selecting proteins with improved stability by a phage-based method. Nat. Biotechnol. 16, 955-960 (1998). (Pubitemid 28483625)
24. Chautard, H. et al. An activity-independent selection system of thermostable protein variants. Nat. Methods 4, 919-921 (2007).
25. Foit, L. et al. Optimizing protein stability in vivo. Mol. Cell 36, 861-871 (2009).
26. Cornvik, T. et al. Colony filtration blot: a new screening method for soluble protein expression in Escherichia coli. Nat. Methods 2, 507-509 (2005).
27. Vedadi, M. et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl Acad. Sci. USA 103, 15835-15840 (2006). (Pubitemid 44657553)
28. Pantoliano, M. W. et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen 6, 429-440 (2001). (Pubitemid 34052847)
29. Senisterra, G. A. et al. Screening for ligands using a generic and highthroughput light-scattering-based assay. J. Biomol. Screen 11, 940-948 (2006). (Pubitemid 44847148)
30. Barthelemy, P. A. et al. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J. Biol. Chem. 283, 3639-3654 (2008).
31. Dimitrov, D. S. Engineered CH2 domains (nanoantibodies). mAbs 1, 26-28 (2009).
32. Tokuriki, N., Oldfield, C. J., Uversky, V. N., Berezovsky, I. N. & Tawfik, D. S. Do viral proteins possess unique biophysical features? Trends Biochem. Sci. 34, 53-59 (2009).
33. Miyazaki, K. Creating random mutagenesis libraries by megaprimer PCR of whole plasmid (MEGAWHOP). Methods Mol. Biol. 231, 23-28 (2003).
34. Ericsson, U. B., Hallberg, B. M., Detitta, G. T., Dekker, N. & Nordlund, P. Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal. Biochem. 357, 289-298 (2006). (Pubitemid 44430091)
35. Colwill, K. & Graslund, S. A roadmap to generate renewable protein binders to the human proteome. Nat. Methods 8, 551-558 (2011).
36. Holliger, P. & Hudson, P. J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23, 1126-1136 (2005). (Pubitemid 41486394)
37. Worn, A. & Pluckthun, A. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 305, 989-1010 (2001). (Pubitemid 33028934)
38. Latypov, R. F. et al. Biophysical characterization of structural properties and folding of interleukin-1 receptor antagonist. J. Mol. Biol. 368, 1187-1201 (2007). (Pubitemid 46574654)
39. Raibekas, A. A. et al. Anion binding and controlled aggregation of human interleukin-1 receptor antagonist. Biochemistry 44, 9871-9879 (2005). (Pubitemid 41033453)
40. Chang, B. S., Reeder, G. & Carpenter, J. F. Development of a stable freeze-dried formulation of recombinant human interleukin-1 receptor antagonist. Pharm. Res. 13, 243-249 (1996). (Pubitemid 26072145)
41. Krishnan, S. & Raibekas, A. A. Multistep aggregation pathway of human interleukin-1 receptor antagonist: kinetic, structural, and morphological characterization. Biophys. J. 96, 199-208 (2009).
42. Schreuder, H. et al. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 386, 194-200 (1997). (Pubitemid 27131449)
43. Schreuder, H. A. et al. Refined crystal structure of the interleukin-1 receptor antagonist. Presence of a disulfide link and a cis-proline. Eur. J. Biochem. 227, 838-847 (1995).
44. van den Berg, S., Lofdahl, P. A., Hard, T. & Berglund, H. Improved solubility of TEV protease by directed evolution. J. Biotechnol. 121, 291-298 (2006). (Pubitemid 43113101)
45. Aslanidis, C. & de Jong, P. J. Ligation-independent cloning of PCR products (LIC-PCR). Nucleic Acids Res. 18, 6069-6074 (1990).
46. Dahlroth, S. L., Nordlund, P. & Cornvik, T. Colony filtration blotting for screening soluble expression in Escherichia coli. Nat. Protoc. 1, 253-258 (2006).
47. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta. Crystallogr. D. Biol. Crystallogr. 50, 760-763 (1994).
48. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta. Crystallogr. D. Biol. Crystallogr. 66, 213-221 (2010).